Safety evaluation of α-lipoic acid (ALA)

被引:108
作者
Cremer, D. R.
Rabeler, R.
Roberts, A.
Lynch, B.
机构
[1] Degussa Food Ingredients GmbH, D-85354 Freising Weihenstephan, Germany
[2] Cantox Hlth Sci Int, Mississauga, ON L5N 1R9, Canada
关键词
alpha-lipoic acid; thioctic acid; safety; adverse; micronucleus; Ames; acute; toxicity; clastinogenicity; mutagenicity; subchronic; 4-week study;
D O I
10.1016/j.yrtph.2006.06.004
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The safety of the antioxidant alpha-lipoic acid (racemic form) (ALA), also called thioctic acid (CAS RN 1077-28-7) was assessed in acute and subchronic toxicity studies as well as in in vitro and in vivo mutagenicity/genotoxicity studies. ALA was not acutely toxic to rats (LD50 > 2000 mg/kg bw, OECD method 425). Administration of 31.6 or 61.9 mg ALA/kg bw/day for 4 weeks to male/female Wistar rats did not show any adverse effects. Specifically, there was no significant difference between control and treated animals at 31.6 or 61.9 mg ALA/kg bw with regard,to body weight gain, feed consumption, animal behaviour, or haematological and clinical chemistry parameters. Only the high-dose of 121 mg ALA/kg bw was associated with slight alterations in liver enzymes as well as histo pathological effects on the liver and mammary gland. ALA did not possess any mutagenic activity in the Ames assays conducted with various bacterial strains of Salmonella typhimurium Moreover, there was no evidence of genotoxic activity in a mouse micronucleus assay. The results of these studies support the safety of ALA. The no-observed-adverse-effect level (NOAEL) is considered to be 61.9 mg/kg bw/day. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:29 / 41
页数:13
相关论文
共 41 条
  • [1] METHODS FOR DETECTING CARCINOGENS AND MUTAGENS WITH SALMONELLA-MAMMALIAN-MICROSOME MUTAGENICITY TEST
    AMES, BN
    MCCANN, J
    YAMASAKI, E
    [J]. MUTATION RESEARCH, 1975, 31 (06): : 347 - 363
  • [2] The pharmacology of the antioxidant lipoic acid
    Biewenga, GP
    Haenen, GRMM
    Bast, A
    [J]. GENERAL PHARMACOLOGY, 1997, 29 (03): : 315 - 331
  • [3] α-lipoic acid mitigates insulin resistance in Goto-Kakizaki rats
    Bitar, MS
    Wahid, S
    Pilcher, CWT
    Al-Saleh, E
    Al-Mulla, F
    [J]. HORMONE AND METABOLIC RESEARCH, 2004, 36 (08) : 542 - 549
  • [4] Dose-proportionality of oral thioctic acid -: coincidence of assessments via pooled plasma and individual data
    Breithaupt-Grögler, K
    Niebch, G
    Schneider, E
    Erb, K
    Hermann, R
    Blume, HH
    Schug, BS
    Belz, GG
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (01) : 57 - 65
  • [5] Long-term safety of α-lipoic acid (ALA) consumption:: A 2-year study
    Cremer, D. R.
    Rabeler, R.
    Roberts, A.
    Lynch, B.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 46 (03) : 193 - 201
  • [6] DENOLIN-REUBENS R, 1953, Acta Chir Belg, V52, P525
  • [7] Prevention of hypertension, insulin resistance, and oxidative stress by α-lipoic acid
    El Midaoui, A
    de Champlain, J
    [J]. HYPERTENSION, 2002, 39 (02) : 303 - 307
  • [8] Evans Joseph L, 2002, Endocr Pract, V8, P29
  • [9] FUKE H, 1972, NIPPON YAKURIGAKU ZA, V68, P175